A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test

Recent advances in chemotherapy have led to the emergence of new types of anticancer agents. With these advances, cases of side effects that have not been witnessed in the past have emerged. The systems of side effect evaluation and their grading have been based on the existing knowledge, such as th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yasuto, Shimasaki, Takeo, Ishigaki, Yasuhito, Fujimoto, Shino, Takahashi, Yoshimitsu, Kimura, Shiori, Aijo, Keiko, Takayanagi, Mami, Mizuta, Shuichi, Masauji, Togen, Masaki, Yasufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229329/
https://www.ncbi.nlm.nih.gov/pubmed/35743996
http://dx.doi.org/10.3390/medicina58060733
_version_ 1784734717459824640
author Yamamoto, Yasuto
Shimasaki, Takeo
Ishigaki, Yasuhito
Fujimoto, Shino
Takahashi, Yoshimitsu
Kimura, Shiori
Aijo, Keiko
Takayanagi, Mami
Mizuta, Shuichi
Masauji, Togen
Masaki, Yasufumi
author_facet Yamamoto, Yasuto
Shimasaki, Takeo
Ishigaki, Yasuhito
Fujimoto, Shino
Takahashi, Yoshimitsu
Kimura, Shiori
Aijo, Keiko
Takayanagi, Mami
Mizuta, Shuichi
Masauji, Togen
Masaki, Yasufumi
author_sort Yamamoto, Yasuto
collection PubMed
description Recent advances in chemotherapy have led to the emergence of new types of anticancer agents. With these advances, cases of side effects that have not been witnessed in the past have emerged. The systems of side effect evaluation and their grading have been based on the existing knowledge, such as the CTCAE (Common Terminology Standard for Adverse Events) for evaluating adverse drug reactions in cancer chemotherapy clinical trials. Therefore, new types of side effects may be overlooked or underestimated. Blinatumomab is a bispecific T-cell–engager (BiTE) antibody with specificity for CD19 on B cells and CD3 on T cells. Neurological events, such as neuropathy and encephalopathy, are serious side effects of BiTE antibodies. We encountered a case of a 62-year-old woman who experienced short-term memory impairment and dysgraphia after the first blinatumomab administration for Philadelphia chromosome negative (Ph−) B-cell acute lymphoblastic leukemia (ALL). The CTCAE does not include dysgraphia as a classifier for antibody therapies, such as blinatumomab, and immune effector cell-associated neurotoxicity syndrome, which is defined as a Chimeric antigen receptor T cell therapy-related toxicity; dysgraphia is included in the list of symptoms but is not graded. In this case, the severity of dysgraphia differed depending on the complexity of the letters examined. There is no report that the severity of dysgraphia depends on the letters’ complexity, and therefore, it may be overlooked when using simple letters. We have reported the characteristics of dysgraphia in this case and the differences observed when judging different letters.
format Online
Article
Text
id pubmed-9229329
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92293292022-06-25 A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test Yamamoto, Yasuto Shimasaki, Takeo Ishigaki, Yasuhito Fujimoto, Shino Takahashi, Yoshimitsu Kimura, Shiori Aijo, Keiko Takayanagi, Mami Mizuta, Shuichi Masauji, Togen Masaki, Yasufumi Medicina (Kaunas) Case Report Recent advances in chemotherapy have led to the emergence of new types of anticancer agents. With these advances, cases of side effects that have not been witnessed in the past have emerged. The systems of side effect evaluation and their grading have been based on the existing knowledge, such as the CTCAE (Common Terminology Standard for Adverse Events) for evaluating adverse drug reactions in cancer chemotherapy clinical trials. Therefore, new types of side effects may be overlooked or underestimated. Blinatumomab is a bispecific T-cell–engager (BiTE) antibody with specificity for CD19 on B cells and CD3 on T cells. Neurological events, such as neuropathy and encephalopathy, are serious side effects of BiTE antibodies. We encountered a case of a 62-year-old woman who experienced short-term memory impairment and dysgraphia after the first blinatumomab administration for Philadelphia chromosome negative (Ph−) B-cell acute lymphoblastic leukemia (ALL). The CTCAE does not include dysgraphia as a classifier for antibody therapies, such as blinatumomab, and immune effector cell-associated neurotoxicity syndrome, which is defined as a Chimeric antigen receptor T cell therapy-related toxicity; dysgraphia is included in the list of symptoms but is not graded. In this case, the severity of dysgraphia differed depending on the complexity of the letters examined. There is no report that the severity of dysgraphia depends on the letters’ complexity, and therefore, it may be overlooked when using simple letters. We have reported the characteristics of dysgraphia in this case and the differences observed when judging different letters. MDPI 2022-05-29 /pmc/articles/PMC9229329/ /pubmed/35743996 http://dx.doi.org/10.3390/medicina58060733 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Yamamoto, Yasuto
Shimasaki, Takeo
Ishigaki, Yasuhito
Fujimoto, Shino
Takahashi, Yoshimitsu
Kimura, Shiori
Aijo, Keiko
Takayanagi, Mami
Mizuta, Shuichi
Masauji, Togen
Masaki, Yasufumi
A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
title A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
title_full A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
title_fullStr A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
title_full_unstemmed A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
title_short A Case Report on Dysgraphia in a Patient Receiving Blinatumomab: Complex Characters Are Easy to Find in a Handwriting Test
title_sort case report on dysgraphia in a patient receiving blinatumomab: complex characters are easy to find in a handwriting test
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229329/
https://www.ncbi.nlm.nih.gov/pubmed/35743996
http://dx.doi.org/10.3390/medicina58060733
work_keys_str_mv AT yamamotoyasuto acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT shimasakitakeo acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT ishigakiyasuhito acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT fujimotoshino acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT takahashiyoshimitsu acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT kimurashiori acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT aijokeiko acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT takayanagimami acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT mizutashuichi acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT masaujitogen acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT masakiyasufumi acasereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT yamamotoyasuto casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT shimasakitakeo casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT ishigakiyasuhito casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT fujimotoshino casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT takahashiyoshimitsu casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT kimurashiori casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT aijokeiko casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT takayanagimami casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT mizutashuichi casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT masaujitogen casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest
AT masakiyasufumi casereportondysgraphiainapatientreceivingblinatumomabcomplexcharactersareeasytofindinahandwritingtest